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Intellectual disability (ID) affects approximately 1%–3% of humans with a gender bias toward males. Previous studies have identified
mutations in more than 100 genes on the X chromosome in males with ID, but there is less evidence for de novo mutations on the
X chromosome causing ID in females. In this study we present 35 unique deleterious de novo mutations in DDX3X identified by whole
exome sequencing in 38 females with ID and various other features including hypotonia, movement disorders, behavior problems,
corpus callosum hypoplasia, and epilepsy. Based on our findings, mutations in DDX3X are one of the more common causes of ID,
accounting for 1%–3% of unexplained ID in females. Although no de novoDDX3Xmutations were identified inmales, we present three
families with segregating missense mutations in DDX3X, suggestive of an X-linked recessive inheritance pattern. In these families, all
males with the DDX3X variant had ID, whereas carrier females were unaffected. To explore the pathogenic mechanisms accounting
for the differences in disease transmission and phenotype between affected females and affected males with DDX3Xmissense variants,
we used canonicalWnt defects in zebrafish as a surrogatemeasure of DDX3X function in vivo.We demonstrate a consistent loss-of-func-
tion effect of all tested de novo mutations on the Wnt pathway, and we further show a differential effect by gender. The differential
activity possibly reflects a dose-dependent effect of DDX3X expression in the context of functional mosaic females versus one-copy
males, which reflects the complex biological nature of DDX3X mutations.
Intellectual disability (ID) affects approximately 1%–3% of
humans with a gender bias toward males.1–4 It is character-
ized by serious limitations in intellectual functioning and
adaptive behavior, starting before the age of 18 years.5
Though mutations causing monogenic recessive X-linked
intellectual disability (XLID) have been reported in more
than 100 genes,6,7 the identification of conditions caused
by de novo mutations on the X chromosome affecting
females only is limited.8,9
By undertaking a systematic analysis of whole exome
sequencing (WES) data on 820 individuals (461 males,
359 females) with unexplained ID or developmental delay
(from the Department of Human Genetics Nijmegen, the
Netherlands), we identified de novo variants in DDX3X
(MIM: 300160; GenBank: NM_001356.4) in seven females
(1.9% of females). Exome sequencing and data analysis
were performed essentially as previously described,10 and
sequencing was performed in the probands and their
unaffected parents (trio approach).11 To replicate these
findings, we examined a second cohort of 957 individuals
(543 males, 414 females) with intellectual disability or
developmental delay from GeneDx (sequencing methods
as previously published12) and a third cohort of 4,295 indi-
viduals with developmental disorders (2,409 males, 1,886
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females) from the Deciphering Developmental Disorders
(DDD) study (UK).13 In most individuals in these cohorts,
a SNP array or array CGH had been performed as well and,
based on the clinical findings, in several individuals addi-
tional metabolic testing, Fragile X testing, or targeted
Sanger analysis of different genes associated with ID was
completed previously. None of these prior analyses re-
vealed the genetic cause in these individuals. We therefore
refer to the individuals in these cohorts as individuals with
unexplained ID. We identified 12 de novo alleles in
DDX3X in the second cohort (2.9% of females) and 20
de novo alleles in the DDD cohort (1.1% of females).
Consequently, based on our findings, mutations in
DDX3X are one of the more common causes of ID,
accounting for 1%–3% of unexplained ID in females.
Altogether, 39 females with de novo variants in DDX3X
were identified in our three cohorts and no de novo vari-
ants in DDX3X were identified in males (Fisher’s exact
test: p ¼ 4.815 3 109).
To further define this neurodevelopmental disorder,
additional females with de novo DDX3X variants were
collected from other clinical and diagnostic centers in
the Netherlands, Belgium, Germany, Italy, and Canada.
In total, we obtained the complete clinical and molecular
details of 38 females from across cohorts, which we present
in this study. All legal representatives provided informed
consent for the use of the data and photographs, and
the procedures followed are in accordance with relevant
institutional and national guidelines and regulations.
The 38 females had 35 distinct de novo variants in
DDX3X (Table 1). 19 of the 35 different alleles are pre-
dicted to be loss-of-function alleles (9 frameshift mutations
leading to premature stop codon, 6 nonsense mutations,
and 4 splice site mutations that possibly cause exon skip-
ping), suggesting haploinsufficiency as the most likely
pathological mechanism. The other variants, 15 missense
variants and 1 in-frame deletion, are all located in the heli-
case ATP-binding domain or helicase C-terminal domain
(Figure 1). One recurrent missense mutation was present
in three females (c.1126C>T [p.Arg376Cys]), and in two
females the same frameshift mutation, c.1535_1536del
(p.His512Argfs*5), was identified.
Analysis of the clinical data suggested a syndromic
disorder with variable clinical presentation. The females
(age range 1–33 years) showed varying degrees of ID
(mild to severe) or developmental delay with associated
neurological abnormalities, including hypotonia (29/38,
76%), movement disorders comprising dyskinesia, spas-
ticity, and a stiff-legged or wide-based gait (17/38, 45%),
microcephaly (12/38, 32%), behavior problems including
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autism spectrum disorder (ASD), hyperactivity, and aggres-
sion (20/38, 53%), and epilepsy (6/38, 16%). Several
recurrent additional features were noted, including joint
hyperlaxity, skin abnormalities (mosaic-like pigmentary
changes in some females), cleft lip and/or palate, hearing
and visual impairment, and precocious puberty. Abnormal
brain MRIs were reported in various females, with corpus
callosum hypoplasia (13/37, 35%), ventricular enlarge-
ment (13/37, 35%), and evidence of cortical dysplasia
(e.g., polymicrogyria) in four individuals. A summary of
the clinical data is presented in Tables 2 and S1, and facial
profiles of 30 of the 38 females are shown in Figure 2.
Although common dysmorphic features are reported,
there is no consistent recognizable phenotype. Based on
these clinical and molecular data, there is no evidence for
an obvious genotype-phenotype correlation between the
different types of mutations and degree of ID.
DDX3X is known as one of the genes that are able to
escape X inactivation.14,15 X-linked dominant conditions
often show a remarkable variability among affected fe-
males which in particular holds true for genes that escape
X inactivation.9,16 It is known that most of the transcripts
escaping X inactivation are not fully expressed from the
inactivated X chromosome, which means that the escape
is often partial and incomplete.9 Based on this, phenotypic
severity might be influenced by the amount of gene
expression of DDX3X in females, which could be affected
by possibly skewed X inactivation or incompleteness of
the escape. Different expression of DDX3X in different
tissues could also be a contributing factor. To further
explore the possible skewing of X inactivation, we deter-
mined X inactivation via the androgen receptor gene
(AR) methylation assay17 on DNA from lymphocytes in
15 females. We found an almost complete skewing
(>95%) of X inactivation in seven individuals and random
skewing in the remainder. This is more than would be ex-
pected by chance, because it is known that a high degree
of skewing of X inactivation is a statistically rare event in
young women.18 However, in our affected females, there
is no evidence of correlation of skewing of X inactivation
with disease severity.
Given the high frequency (1%–2%) of DDX3X muta-
tions in females with unexplained ID, we sought to
determine whether males carry deleterious alleles. We
identified no de novo variants in DDX3X males in any of
our cohorts. However, upon sequencing of the X chromo-
some (X-exome) of ID-affected families with apparent
X-linked inheritance pattern,7 we identified two families
with segregating missense variants in DDX3X. Moreover,
one additional family was identified by diagnostic whole
exome sequencing in Antwerp, Belgium. In these three
families, males with the DDX3X variant have borderline
to severe ID and carrier females are unaffected. Pedigrees
of these three families are shown in Figure S1, and a sum-
mary of the clinical features of the affected males is pre-
sented in Table S2. All three missense mutations were
predicted to be deleterious by prediction programs Poly-
Phen-2 and SIFT (Table 1) and map within the helicase
ATP-binding domain (Figure 2). With three-dimensional
protein analysis, we could not discern any clear difference
between the missense mutations found in affected males
and the de novo mutations found in females that could
possibly explain the gender-specific pathogenicity
(Figure S2, Table S3). Although in the first two families
with affected males the phenotype consisted mainly of in-
tellectual disability, family 3 was more complex. The male
proband had severe ID and various other features such as a
dysplastic pulmonary valve, hypertonia, and strabismus.
In this male a SNP-array analysis was performed, as well
as DNA analysis of PTEN (MIM: 601728) and FMR1
(MIM: 309550) andmethylation studies on Angelman syn-
drome (MIM: 105830), all without abnormalities. With
exome sequencing no other candidate genes were found.
Hismother had recurrentmiscarriages of unknown gender.
A second initially viable pregnancy was terminated
because of ultrasound anomalies that had also been noted
in the proband, including a thickened nuchal fold and ab-
sent nasal bone. After termination of the pregnancy, the
male fetus was tested and found to have the samemissense
mutation in DDX3X as his brother. Sequencing of other
family members demonstrated that the mutation arose
de novo in the proband’s mother. X-inactivation studies
in this mother demonstrated a random X-inactivation
pattern (68/32). X-inactivation studies in female carriers
in the other families showed that in family 1, the obligate
carrier female (II-2) had highly skewed X inactivation
(>95%), whereas X-inactivation studies in family 2 were
not informative.
None of the three DDX3X variants found in these
families with affected males were reported in the ExAC
database or in the Exome Variant Server (ESP), nor was
one of the de novo variants found in females reported in
these databases. Moreover, none of the DDX3Xmutations
identified in males were detected in affected females. As far
as we are aware, in addition to the de novo missense muta-
tion identified in family 3, no other de novo mutations
in DDX3X are reported in healthy individuals or control
cohorts. We downloaded all variants from the ExAC data-
base, containing exome data of 60,706 individuals, and
calculated per gene the number of missense and synony-
mous variants. These numbers were then normalized by
dividing through the total number of possible missense
and synonymous variants per gene. The ratio of corrected
missense over synonymous variants was then used as a
measure for tolerance of the gene to normal variation,
similarly as was done previously.19 When genes were
ranked according to their tolerance score, DDX3X was
among the most intolerant genes (1.09% of genes, rank
194 out of 17,856), showing that normal variation in this
gene is extremely rare.
DDX3X encodes a conserved DEAD-box RNA helicase
important in a variety of fundamental cellular processes
that include transcription, splicing, RNA transport, and
translation.20,21 DDX3X has been associated with many
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Table 1. Mutation Characteristics
Nucleotide Change
(GenBank:
NM_001356.4) Amino Acid Change SIFT PolyPhen-2 Cohort
Previously
Reported
Females
Individual 1 c.1126C>T p.Arg376Cys not tolerated probably damaging Nijmegen –
Individual 2 c.233C>G p.Ser78* NA NA Nijmegen –
Individual 3 c.1126C>T p.Arg376Cys not tolerated probably damaging DDD Study DDD Study13
Individual 4 c.136C>T p.Arg46* NA NA DDD Study DDD Study13
Individual 5 c.1601G>A p.Arg534His not tolerated probably damaging DDD Study DDD Study13
Individual 6 c.641T>C p.Ile214Thr not tolerated probably damaging DDD Study DDD Study13
Individual 7 c.1520T>C p.Ile507Thr not tolerated probably damaging other –
Individual 8 c.977G>A p.Arg326His not tolerated probably damaging other –
Individual 9 c.868del p.Ser290Hisfs*31 NA NA other Rauch et al.41
Individual 10 c.1229_1230dup p.Thr411Leufs*10 NA NA Nijmegen –
Individual 11 c.1105dup p.Thr369Asnfs*14 NA NA Nijmegen –
Individual 12 c.8652A>G p.? NA NA Nijmegen –
Individual 13 c.1600dup p.Arg534Profs*13 NA NA other –
Individual 14 c.269dup p.Ser90Argfs*8 NA NA Nijmegen –
Individual 15 c.1440A>T p.Arg480Ser not tolerated probably damaging Nijmegen –
Individual 16 c.873C>A p.Tyr291* NA NA Nijmegen –
Individual 17 c.1693C>T p.Gln565* NA NA Nijmegen –
Individual 18 c.1535_1536del p.His512Argfs*5 NA NA DDD Study –
Individual 19 c.7661G>C p.? NA NA other –
Individual 20 c.599dup p.Tyr200* NA NA USA –
Individual 21 c.1321del p.Asp441Ilefs*3 NA NA USA –
Individual 22 c.1383dup p.Tyr462Ilefs*3 NA NA USA –
Individual 23 c.1384_1385dup p.His463Thrfs*34 NA NA USA –
Individual 24 c.1535_1536del p.His512Argfs*5 NA NA USA –
Individual 25 c.1541T>C p.Ile514Thr not tolerated probably damaging USA –
Individual 26 c.704T>C p.Leu235Pro not tolerated probably damaging USA –
Individual 27 c.1175T>C p.Leu392Pro not tolerated probably damaging USA –
Individual 28 c.1463G>A p.Arg488His not tolerated possibly damaging USA –
Individual 29 c.1126C>T p.Arg376Cys not tolerated probably damaging USA –
Individual 30 c.1250A>C p.Gln417Pro not tolerated probably damaging USA –
Individual 31 c.698C>T p.Ala233Val not tolerated probably damaging DDD Study –
Individual 32 c.931C>T p.Arg311* NA NA DDD Study –
Individual 33 c.46-2A>C p.? NA NA DDD Study –
Individual 34 c.1678_1680del p.Leu560del NA NA DDD Study –
Individual 35 c.1423C>G p.Arg475Gly not tolerated probably damaging DDD Study –
Individual 36 c.46-2A>G p.? NA NA DDD Study –
Individual 37 c.1703C>T p.Pro568Leu not tolerated probably damaging DDD Study –
Individual 38 c.1526A>T p.Asn509Ile not tolerated probably damaging DDD Study –
(Continued on next page)
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cellular processes, such as cell cycle control, apoptosis, and
tumorigenesis.22,23 It is also thought to be an essential fac-
tor in the RNAi pathway24 and it is a key regulator of the
Wnt/b-catenin pathway, acting as a regulatory subunit of
CSNK1E and stimulating its kinase activity.25
Notably, of the 35 different de novo variants, 19 alleles
are predicted to give a loss-of-function effect. Antisense-
based knockdown of the DDX3X-ortholog PL10 in zebra-
fish (72% identical, 78% similar) is already described and
shows a reduced brain size and head size in zebrafish em-
bryos at 2 days postfertilization (dpf).13 The missense
changes in affected females were located in the same pro-
tein domain as the missense changes in affected males,
so we explored the pathogenic mechanisms accounting
for the differences in disease transmission and phenotype
between affected females and affected males with DDX3X
missense variants. We therefore employed a combination
of in vitro and in vivo assays based on the known role of
DDX3X in the regulation of Wnt/b-catenin signaling.25
Wnt signaling is a critical developmental pathway;
the zebrafish is a tractable model in which to study Wnt
output26–31 and to interrogate alleles relevant to neurocog-
nitive traits.32 We tested several representative missense
variants, including the female-specific de novo vari-
ants c.641T>C (p.Ile214Thr), c.977G>A (p.Arg326His),
c.1126C>T (p.Arg376Cys), c.1520T>C (p.Ile507Thr), and
c.1601G>A (p.Arg534His) as well as the inherited variants
c.898G>T (p.Val300Phe), c.1052G>A (p.Arg351Gln), and
c.1084C>T (p.Arg362Cys) identified in males. A variant
from the Exome Variant Server (c.586G>A [p.Glu196Lys])
was chosen as a negative control (rs375996245; MAF <
0.002).
We first tested whether the missense variants identified
in our ID cohort resulted in dominant effects by overex-
pressing either WT or mutant DDX3X human transcript
in zebrafish embryos and examining the phenotype. Ze-
brafish (Danio rerio) were raised and mated as described.33
Embryos from ZDR strain fish were injected into the
yolk with 1 nl of solution containing mRNA at the 1- to
2-cell stage using a Picospritzer III microinjector (Parker).
The wild-type (WT) human DDX3X open reading frame
(ORF) construct was obtained from the Ultimate ORF
Collection (LifeTechnologies; clone ID: IOH13891),
sequenced fully, and sub-cloned into the pCS2þ vector
using Gateway LR clonase II- mediated cloning (LifeTech-
nologies). Capped mRNA was generated using linearized
constructs as a template with the mMessage mMachine
SP6 transcription kit (LifeTechnologies). Injection of 100
pg of WT or mutant DDX3X transcripts did not produce
a discernible phenotype at 36 hr postfertilization (hpf)
(n¼ 50–75 embryos/injection; repeated twice withmasked
scoring; Figure S3A) or at 72 hpf (not shown). To corrobo-
rate these data in a different system, we used a mammalian
cell-based assay of canonical Wnt signaling (TOPFlash).34
In brief, HEK293T cells and mouse L-cells (both control
and WNT3A expressing) were grown in 10% FBS/DMEM.
WNT3A-containing media was prepared by incubating
confluent L-cells with serum-free media for 24 hr and
removing and filtering the media. This was subsequently
used to stimulate transfected HEK293Tcells. HEK293Tcells
Table 1. Continued
Nucleotide Change
(GenBank:
NM_001356.4) Amino Acid Change SIFT PolyPhen-2 Cohort
Previously
Reported
Males
Family 1 c.1084C>T p.Arg362Cys not tolerated probably damaging – –
Family 2 c.1052G>A p.Arg351Gln not tolerated possibly damaging – Hu et al.7
Family 3 c.898G>T p.Val300Phe not tolerated probably damaging – –
‘‘Other’’ indicates additional females with de novo DDX3Xmutations collected from different diagnostic centers in the Netherlands, Belgium, Germany, Italy, and
Canada.
Figure 1. Location of Amino Acid Substi-
tutions in DDX3X
Schematic view of DDX3X with the 15
different amino acid substitutions (and
one in-frame deletion) found in affected
females and the 3 different amino acid sub-
stitutions found in affected males. DDX3X
consists of two subdomains: a helicase
ATP-binding domain and a helicase C-ter-
minal domain. All amino acid substitu-
tions found in affected females are located
within these two protein domains. The
three amino acid substitutions found in
affected males are all located within the
helicase ATP-binding domain.
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at a density of 1 3 104 cells/well on 24-well plates were
transfected with 1.025 mg total of DNA containing 0.5 mg
of pGL4.18 TOPFLASH vector, 25 ng of renilla luciferase
plasmid (pRL-SV40), and 0.5 mg of pCS2þ with or without
DDX3X using XtremeGene9 (Roche). After 24 hr the me-
dia was removed and replaced with serum-free media
collected as above from L-cells with and without WNT3A
(MIM: 606359). After 24 hr, cells were harvested and
luciferase activity measured by the Dual-Luciferase Re-
porter Assay System (Promega). Results were normalized
internally for each well to renilla luciferase activity and
then to the unstimulated wells (conditioned with control
L-cell media). Consistent with the in vivo result, transfec-
tion of expression constructs harboring DDX3X variants
did not differ from WT in the modulation of WNT3A-
b-catenin mediated luciferase activity (Figure S3B; tripli-
cate wells with 3–5 biological replicates). Taken together,
our results suggest that neither the female nor the male
DDX3X variants produce detectable dominant changes
in the context of Wnt signaling. These results are in line
with the high number of de novo truncating mutations
in females, suggesting haploinsufficiency as themost likely
pathogenic mechanism. As a consequence, we pursued a
loss-of-function paradigm.
Previous studies have shown that co-expression of a
canonical Wnt ligand and DDX3X is necessary to produce
a phenotype in vivo.25 Expression of either of the canoni-
cal Wnt ligandsWNT3A orWNT8A (MIM: 606360) results
in ventralization of zebrafish embryos that ranges from
mild (hypoplasia of the eyes, which we term class I em-
bryos) to moderate (absence of one or both eyes; class II),
severe (loss of all anterior neural structures; class III), and
radialized (class IV) phenotypes at 2 dpf.28 We recapitu-
lated these defects by injecting increasing doses of human
WNT3A or WNT8A mRNA into embryos (Figures 3A
and 3B). Full-length human WNT3A and WNT8A ORFs
were cloned into pCS2þ from the Ultimate ORF Collec-
tion (Clone ID WNT8A: IOH35591; Clone ID WNT3A:
IOH80731). The WNT3A clone required site-directed
mutagenesis to introduce a stop codon using primers
(50-ctgcaaggccgccaggcacTAGGGTGGGCGCGCCGA-30 and
its reverse complement). We selected a dose of WNT3A
mRNA (200 fg), which produced a modest effect (15%–
20% class IþII embryos, no class III or IV) and we co-
injected it with progressively increasing concentrations
of human DDX3X mRNA. At 2 dpf, we observed a dose-
response curve concomitant with increasing doses
of DDX3X (Figure 3D). At low doses of mutant DDX3X
(15–20 pg/embryo), the ventralization phenotype pro-
duced by WNT3A is exacerbated, producing 40%–50%
class IþII embryos, with a greater percentage in class II
(10%–15%), indicative of augmented severity (Figure 3D).
Because of the significant (p < 0.0001) augmentation of
WNT3A-mediated ventralization at 15 pg of DDX3X, we
next used this combination of doses to test the effect of
the missense alleles on Wnt signaling. WNT3A mRNA
(200 fg) was co-injected with 15 pg of WT or variant
DDX3X mRNA, and we scored embryos for ventralization
at 2dpf.We founddifferential effects of the variants on ven-
tralization (Figure 3E; triplicate experiments; pooled for the
final result). All de novo variants tested were significantly
different from WT (p < 0.001) and indistinguishable from
WNT3A alone, suggesting that they all confer complete
loss of function toDDX3X. By contrast, the control variant
c.586G>A (p.Glu196Lys) resulted in phenotypes similar
to WT. Notably, all three inherited variants found in the
affected males were also indistinguishable from WT in-
jected and each was statistically different from WNT3A
alone (p < 0.0001). Given this apparent dichotomization
of effect between female denovo andmale inherited alleles,
we tested whether pooling of results from the female versus
male variants would exhibit a ‘‘class effect’’ separation
between the two groups. We found this to be true; there
was significant differential effect of the gender-specific
sets of variants on Wnt signaling (Figure 3F).
Table 2. Clinical Features of Females with De Novo DDX3X
Mutations
Percentage Number
Development
Intellectual disability or developmental delay 100% 38/38
Mild or mild-moderate disability 26% 10/38
Moderate or moderate-severe disability 26% 10/38
Severe disability 40% 15/38
Developmental delay 8% 3/38
Growth
Low weight 32% 12/38
Microcephaly 32% 12/38
Neurology
Hypotonia 76% 29/38
Epilepsy 16% 6/38
Movement disorder (including spasticity) 45% 17/38
Behavior problems 53% 20/38
Brain MRI
Corpus callosum hypoplasia 35% 13/37
Cortical malformation 11% 4/37
Ventricular enlargement 35% 13/37
Other
Skin abnormalities 37% 14/38
Hyperlaxity 37% 14/38
Visual problems 34% 13/38
Hearing loss 8% 3/38
Cleft lip or palate 8% 3/38
Precocious puberty 13% 5/38
Scoliosis 11% 4/38
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Taken together, our in vivo testing of the nonsynony-
mous DDX3X mutations demonstrated marked alteration
in Wnt-mediated ventralization for changes arising de
novo in affected females. Our data also reinforce the
notion that disruption of b-catenin signaling during
neurodevelopment has profound consequences. Loss of
Wnt signaling inhibits neuroblast migration, neural
differentiation, and suppression of the development of
the forebrain.35–38 Moreover, we previously reported that
mutations in b-catenin contribute to ID in humans,39,40
and mutations in d-catenin, some of which abrogate its
biochemical interaction with b-catenin, can contribute to
severe autism in females,32 strengthening further the link
between Wnt signaling and human neurodevelopmental
disorders.
DDX3X has recently been proposed as a candidate ID
gene.13,41 Our data substantiate this hypothesis and sug-
gest that mutated DDX3X is among the most common
causes of simplex cases of intellectual disability in females.
Our data also suggest that the genetic architecture of
DDX3X-mediated pathology in males is different. All
Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 Individual 7 
Individual 8 Individual 9 Individual 10 Individual 11 Individual 12 Individual 13 
Individual 14 Individual 15 Individual 16 Individual 17 Individual 18 Individual 19 
Individual 20 Individual 22 Individual 23 Individual 24 Individual 26 Individual 27 
Individual 31 Individual 32 Individual 33 Individual 34 Individual 35 Individual 37 
Figure 2. Facial Profiles of Females with
De Novo DDX3X Mutations
Facial features of 30 of 38 females with a de
novo variant in DDX3X. Common facial
features include a long and/or hypotonic
face (e.g., individuals 2, 4, 5, 12, 22, 32),
a high and/or broad forehead (e.g., individ-
uals 1, 7, 9, 23, 24, 26), a wide nasal
bridge and/or bulbous nasal tip (e.g., indi-
viduals 11, 13, 15, 16), narrow alae nasi
and/or anteverted nostrils (e.g., individ-
uals 2, 8, 9, 12, 14, 18, 24, 27, 32, 35),
and hypertelorism (e.g., individuals 5,
7, 8, 20, 27). Informed consent was
obtained for all 30 individuals shown.
The individual numbers correspond to the
numbers mentioned in Tables 1 and S1.
detected male alleles were inherited
from unaffected mothers, suggesting
either a gender-specific buffering
effect or a milder effect of those
inherited alleles on protein function.
Both our in vivo and our in vitro
studies indicate that none of the
tested alleles (male or female) confer
dominant effects and that the male
alleles are indistinguishable from WT
in our system. Given that human ge-
netics and computational predictions
support the causality of these alleles
in the families studied, we speculate
that the effect of these alleles is
beyond the dynamic range of our as-
says and thus could not be detected;
a substantially larger assay of embryos
might detect a signal, although the
transient nature of our system will always be limited at
detecting mild allele effects. Alternatively, the mechanism
of the male-derived alleles might be qualitatively different
from the de novo female variants and reflective of the
complex biology of DDX3X. Of note, we found that
increased amounts of wild-type DDX3X ameliorated the
Wnt3a-induced ventralization phenotype (Figure S4B),
an observation that we reproduced with Wnt8a, another
b-catenin-dependent ligand (Figure S4A) and our TOPFlash
reporter assay (Figure S3B). This bimodal activity of
DDX3X has been intimated previously by Cruciat et al.,
in which knockdown of DDX3X caused loss of WNT3A
signaling that was restored by transfection with WT
construct whereas overexpression alone resulted in
decreased WNT3A signaling.25 We reproduced this latter
finding when solely overexpressing DDX3X in HEK293
cells (Figure S3B).
Summarized, these data suggest that DDX3X is dosage
sensitive and might have a differential activity in females
than in males. Contribution of the DDX3X homolog at
the Y chromosome,DDX3Y (MIM: 400010), to phenotypic
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variability is unlikely.42 DDX3X and DDX3Y have 92%
amino acid sequence in common14 but DDX3Y is trans-
lated only in spermatocytes and is essential for spermato-
genesis.43,44 Deletions or mutations of DDX3Y cause
spermatogenic failure but are not associated with cognitive
dysfunction or other abnormalities.44,45
In conclusion, de novo variants inDDX3X are a frequent
cause of intellectual disability, affecting 1%–3% of all so far
unexplained ID in females. Although no de novo muta-
tions were identified in males, we found missense variants
in DDX3X in males from three families with ID suggestive
of X-linked recessive inheritance. Our phenotypic read
out in zebrafish shows a gender difference in identified
variants with a loss-of-function effect of all tested de
novo mutations on the Wnt pathway. The differential
activity possibly indicates a dose-dependent effect of
DDX3X expression in the context of functional mosaic
females versus one-copy males, which reflects the complex
biological nature of pathogenic DDX3X variants.
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